Avicanna (AVCN.TO) on Thursday launched its QUIX-powered rapid-onset medical cannabis portfolio, with initial SKUs to be available in Canada from the third quarter of this year.
QUIX is Avicanna's drug delivery technology developed to overcome challenges associated with cannabinoid delivery, like poor water solubility and low and variable bioavailability.
The new portfolio reflects Avicanna's focus on developing standardized, accurately dosed, and non-combustible product formats for its medical cannabis portfolio, a statement said.
Avicanna shares were last seen up C$0.01, or 8.3%, to C$0.13 on the Toronto Stock Exchange.
Price: $0.13, Change: $+0.01, Percent Change: +8.33%